ResMed Inc.'s income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Jun 30, 2026 · FY), ResMed Inc. reported revenue of $5.7B (+9.9% year on year) and net income of $1.5B (+8.8% year on year).
| Line item | Jun 30, 2026 · FY | Jun 30, 2025 · FY | Jun 30, 2024 · FY | Jun 30, 2023 · FY |
|---|---|---|---|---|
| Net revenue | $5.7B | $5.1B | $4.7B | $4.2B |
| Cost of sales (exclusive of amortization shown separately below) | $2.2B | $2.1B | $2.0B | $1.8B |
| Amortization of acquired intangible assets | $31.8M | $32.1M | $33.0M | $30.4M |
| Total cost of sales | $2.2B | $2.1B | $2.0B | $1.9B |
| Gross profit | $3.5B | $3.1B | $2.7B | $2.4B |
| Research and development | $378.3M | $331.3M | $307.5M | $287.6M |
| Selling, general, and administrative | $1.1B | $991.0M | $917.1M | $874.0M |
| Amortization of acquired intangible assets | $45.5M | $45.3M | $46.5M | $42.0M |
| Restructuring expenses (note 17) | $21.7M | $0 | $64.2M | — |
| Total operating expenses | $1.6B | $1.4B | $1.3B | $1.2B |
| Income from operations | $1.9B | $1.7B | $1.3B | $1.1B |
| Interest income (expense), net | $49.9M | $4.1M | ($45.7M) | — |
| Gain (loss) attributable to equity method investments (note 6) | $7.0M | $3.6M | ($1.8M) | ($7.3M) |
| Gain (loss) on equity investments (note 6) | ($15.0M) | ($10.3M) | ($4.0M) | $9.9M |
| Other, net | ($9.2M) | ($5.3M) | ($3.5M) | ($5.7M) |
| Total other income (loss), net | $32.7M | ($7.8M) | ($55.1M) | ($30.2M) |
| Income before income taxes | $1.9B | $1.7B | $1.3B | $1.1B |
| Income taxes (note 12) | $396.1M | $276.8M | $243.8M | $204.1M |
| Net income | $1.5B | $1.4B | $1.0B | $897.6M |
| Basic earnings per share (note 11) (in dollars per share) | $10.47 | $9.55 | $6.94 | $6.12 |
| Diluted earnings per share (note 11) (in dollars per share) | $10.43 | $9.51 | $6.92 | $6.09 |
| Dividend declared per share (in dollars per share) | $2.40 | $2.12 | $1.92 | $1.76 |
| Basic shares outstanding (000's) (in shares) | 145.5M | 146.7M | 147.0M | 146.8M |
| Diluted shares outstanding (000's) (in shares) | 146.1M | 147.3M | 147.6M | 147.5M |
| Line item | Mar 31, 2026 · Q3 | Dec 31, 2025 · Q2 | Sep 30, 2025 · Q1 | Mar 31, 2025 · Q3 |
|---|---|---|---|---|
| Net revenue | $1.4B | $1.4B | $1.3B | $1.3B |
| Cost of sales (exclusive of amortization shown separately below) | $532.6M | $536.3M | $506.9M | $517.9M |
| Amortization of acquired intangible assets | $7.8M | $7.8M | $7.8M | $7.4M |
| Total cost of sales | $540.4M | $544.1M | $514.8M | $525.3M |
| Gross profit | $891.0M | $878.7M | $820.8M | $766.4M |
| Selling, general, and administrative | $285.7M | $278.4M | $259.2M | $245.3M |
| Research and development | $94.3M | $91.0M | $87.3M | $83.9M |
| Amortization of acquired intangible assets | $11.2M | $11.8M | $12.0M | $10.9M |
| Restructuring expenses (note 11) | $0 | $5.9M | $15.8M | $0 |
| Total operating expenses | $391.2M | $387.1M | $374.3M | $340.1M |
| Income from operations | $499.8M | $491.7M | $446.5M | $426.3M |
| Interest (expense) income, net | $12.3M | $7.9M | $8.8M | $793.0K |
| Gain (loss) attributable to equity method investments (note 5) | $1.7M | $1.5M | $1.5M | $335.0K |
| Gain (loss) on equity investments (note 5) | ($10.1M) | $306.0K | ($6.2M) | ($5.6M) |
| Other, net | ($1.4M) | ($5.3M) | ($3.8M) | ($4.1M) |
| Total other income (loss), net | $2.5M | $4.5M | $256.0K | ($8.6M) |
| Income before income taxes | $502.3M | $496.1M | $446.8M | $417.7M |
| Income taxes | $103.6M | $103.6M | $98.3M | $52.7M |
| Net income | $398.7M | $392.6M | $348.5M | $365.0M |
| Basic earnings per share (in dollars per share) | $2.74 | $2.69 | $2.38 | $2.49 |
| Diluted earnings per share (in dollars per share) | $2.74 | $2.68 | $2.37 | $2.48 |
| Dividend declared per share (in dollars per share) | $0.60 | $0.60 | $0.60 | $0.53 |
| Basic shares outstanding (000's) (in shares) | 145.3M | 145.8M | 146.2M | 146.7M |
| Diluted shares outstanding (000's) (in shares) | 145.7M | 146.4M | 146.9M | 147.2M |
| Line item | Jun 30, 2026 · FY | Jun 30, 2025 · FY | Jun 30, 2024 · FY | Jun 30, 2023 · FY |
|---|---|---|---|---|
| Cash and cash equivalents | $1.5B | $1.2B | $238.4M | $227.9M |
| Accounts receivable, net of allowances of $25,839 and $22,424 at June 30, 2026 and June 30, 2025, respectively | $1.0B | $939.5M | $837.3M | $704.9M |
| Inventories (note 4) | $945.8M | $927.7M | $822.3M | $998.0M |
| Prepaid expenses and other current assets (note 4) | $416.1M | $429.0M | $459.8M | $437.0M |
| Assets held for sale (note 18) | $457.4M | — | — | — |
| Total current assets | $4.3B | $3.5B | $2.4B | $2.4B |
| Property, plant and equipment, net (note 4) | $581.8M | $550.8M | $548.0M | $537.9M |
| Operating lease right-of-use assets (note 9) | $153.2M | $167.5M | $151.1M | $128.0M |
| Goodwill (note 5) | $2.9B | $3.0B | $2.8B | $2.8B |
| Other intangible assets, net (note 5) | $452.7M | $464.9M | $485.9M | $552.3M |
| Deferred income taxes (note 12) | $329.3M | $253.1M | $203.6M | $133.0M |
| Prepaid taxes and other non-current assets | $214.6M | $185.8M | $284.0M | $262.5M |
| Total non-current assets | $4.6B | $4.7B | $4.5B | $4.4B |
| Total assets | $9.0B | $8.2B | $6.9B | $6.8B |
| Accounts payable | $308.9M | $278.2M | $237.7M | $150.8M |
| Accrued expenses (note 7) | $494.9M | $402.3M | $377.7M | $365.7M |
| Operating lease liabilities, current (note 9) | $29.1M | $30.5M | $25.3M | $21.9M |
| Deferred revenue | $162.9M | $166.0M | $152.6M | $138.1M |
| Income taxes payable (note 12) | $98.1M | $132.3M | $107.5M | $72.2M |
| Short-term debt, net (note 8) | $259.9M | $9.9M | $9.9M | $9.9M |
| Liabilities held for sale (note 18) | $41.2M | — | — | — |
| Total current liabilities | $1.4B | $1.0B | $910.7M | $758.5M |
| Deferred revenue | $171.0M | $156.8M | $137.3M | $119.2M |
| Deferred income taxes (note 12) | $64.6M | $77.7M | $79.3M | $90.7M |
| Operating lease liabilities, non-current (note 9) | $137.4M | $153.0M | $141.4M | $116.9M |
| Other long-term liabilities | $213.0M | $141.5M | $42.3M | $68.2M |
| Long-term debt, net (note 8) | $399.4M | $658.4M | $697.3M | $1.4B |
| Total non-current liabilities | $985.4M | $1.2B | $1.1B | $1.9B |
| Total liabilities | $2.4B | $2.2B | $2.0B | $2.6B |
| Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued | 0 | 0 | 0 | 0 |
| Common stock, $0.004 par value, 350,000,000 shares authorized; 191,037,523 issued and 144,239,563 outstanding at June 30, 2026 and 190,311,097 issued and 146,385,350 outstanding at June 30, 2025 | 764.0K | 761.0K | 588.0K | 588.0K |
| Additional paid-in capital | $2.2B | $2.0B | $1.9B | $1.8B |
| Retained earnings | $7.3B | $6.1B | $5.0B | $4.3B |
| Treasury stock, at cost, 46,798,043 shares at June 30, 2026 and 43,925,747 shares at June 30, 2025 | -2.8B | -2.1B | -1.8B | -1.6B |
| Accumulated other comprehensive loss | ($82.5M) | ($74.7M) | ($251.5M) | ($272.5M) |
| Total stockholders’ equity | $6.6B | $6.0B | $4.9B | $4.1B |
| Total liabilities and stockholders’ equity | $9.0B | $8.2B | $6.9B | $6.8B |
| Line item | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Mar 31, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | $1.7B | $1.4B | $1.4B | $932.7M |
| Accounts receivable, net of allowances of $29,474 and $22,424 at March 31, 2026 and June 30, 2025, respectively | $998.8M | $985.6M | $907.3M | $907.8M |
| Inventories (note 3) | $911.9M | $922.0M | $945.8M | $862.6M |
| Prepaid expenses and other current assets (note 3) | $492.8M | $494.1M | $388.8M | $505.2M |
| Total current assets | $4.1B | $3.8B | $3.6B | $3.2B |
| Property, plant and equipment, net (note 3) | $567.0M | $564.3M | $563.6M | $535.3M |
| Operating lease right-of-use assets | $161.6M | $165.9M | $162.0M | $152.6M |
| Goodwill (note 4) | $3.0B | $3.0B | $3.0B | $2.8B |
| Other intangible assets, net (note 3) | $425.2M | $430.2M | $447.1M | $430.1M |
| Deferred income taxes | $312.6M | $285.9M | $275.9M | $216.8M |
| Prepaid taxes and other non-current assets | $210.7M | $193.9M | $189.8M | $174.6M |
| Total non-current assets | $4.7B | $4.7B | $4.7B | $4.4B |
| Total assets | $8.8B | $8.5B | $8.3B | $7.6B |
| Accounts payable | $273.3M | $250.4M | $266.8M | $222.6M |
| Accrued expenses | $446.1M | $391.5M | $395.8M | $386.3M |
| Operating lease liabilities, current | $29.2M | $29.8M | $30.0M | $28.7M |
| Deferred revenue | $179.3M | $176.1M | $167.8M | $160.4M |
| Income taxes payable | $163.3M | $140.5M | $135.2M | $132.5M |
| Short-term debt, net (note 7) | $259.9M | $259.9M | $259.9M | $9.9M |
| Total current liabilities | $1.4B | $1.2B | $1.3B | $940.5M |
| Deferred revenue | $163.1M | $159.8M | $159.4M | $151.1M |
| Deferred income taxes | $77.9M | $78.0M | $77.6M | $79.0M |
| Operating lease liabilities, non-current | $149.8M | $154.1M | $147.8M | $138.0M |
| Other long-term liabilities | $146.1M | $138.5M | $138.2M | $49.0M |
| Long-term debt, net (note 7) | $404.2M | $403.9M | $408.7M | $663.1M |
| Total non-current liabilities | $941.2M | $934.4M | $931.6M | $1.1B |
| Total liabilities | $2.3B | $2.2B | $2.2B | $2.0B |
| Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued | 0 | 0 | 0 | 0 |
| Common stock, $0.004 par value, 350,000,000 shares authorized; 190,866,303 issued and 145,040,224 outstanding at March 31, 2026 and 190,311,097 issued and 146,385,350 outstanding at June 30, 2025 | 763.0K | 763.0K | 762.0K | 761.0K |
| Additional paid-in capital | $2.1B | $2.1B | $2.1B | $2.0B |
| Retained earnings | $7.0B | $6.6B | $6.3B | $5.8B |
| Treasury stock, at cost, 45,826,079 shares at March 31, 2026 and 43,925,747 shares at June 30, 2025 | -2.6B | -2.4B | -2.2B | -2.0B |
| Accumulated other comprehensive loss | ($24.9M) | ($29.9M) | ($60.7M) | ($250.9M) |
| Total stockholders’ equity | $6.5B | $6.3B | $6.1B | $5.5B |
| Total liabilities and stockholders’ equity | $8.8B | $8.5B | $8.3B | $7.6B |
| Line item | Jun 30, 2026 · FY | Jun 30, 2025 · FY | Jun 30, 2024 · FY | Jun 30, 2023 · FY |
|---|---|---|---|---|
| Net income | $1.5B | $1.4B | $1.0B | $897.6M |
| Depreciation and amortization | $201.3M | $198.5M | $176.9M | $165.2M |
| Amortization of right-of-use assets | $42.8M | $37.3M | $39.3M | $32.4M |
| Stock-based compensation costs (note 10) | $104.3M | $91.7M | $80.2M | $71.1M |
| (Gain) loss attributable to equity method investments, net of dividends received (note 6) | ($2.4M) | ($3.6M) | $1.8M | — |
| (Gain) loss on equity investments (note 6) | $15.0M | $10.3M | $4.0M | — |
| Gain on previously held equity investment (note 6) | ($4.4M) | — | — | — |
| Restructuring expenses (note 17) | $0 | $0 | $33.2M | — |
| Accounts receivable | ($96.8M) | ($76.7M) | ($134.3M) | ($106.5M) |
| Inventories | ($9.9M) | ($80.2M) | $172.2M | ($248.8M) |
| Prepaid expenses, net deferred income taxes and other current assets | ($140.3M) | $82.6M | ($115.2M) | ($138.1M) |
| Accounts payable, accrued expenses and other | $172.7M | $91.0M | $122.1M | $31.3M |
| Net cash provided by (used in) operating activities | $1.8B | $1.8B | $1.4B | $693.3M |
| Purchases of property, plant and equipment | ($156.3M) | ($89.9M) | ($99.5M) | ($119.7M) |
| Patent registration costs | ($18.7M) | — | — | — |
| Purchases of intangible assets | ($2.2M) | ($10.8M) | ($15.4M) | ($14.3M) |
| Business acquisitions, net of cash acquired | ($350.7M) | ($139.2M) | ($133.5M) | ($1.0B) |
| Purchases of investments (note 6) | ($28.5M) | ($6.4M) | ($12.8M) | ($32.2M) |
| Proceeds from exits of investments (note 6) | $2.8M | $4.6M | $1.0M | $3.9M |
| Proceeds (payments) on maturity of foreign currency contracts | $8.5M | $41.6M | ($9.7M) | $15.2M |
| Net cash provided by (used in) investing activities | ($545.2M) | ($200.0M) | ($269.8M) | ($1.2B) |
| Proceeds from issuance of common stock, net | $74.5M | $74.4M | $53.1M | $49.1M |
| Taxes paid related to net share settlement of equity awards | ($21.8M) | ($18.1M) | ($8.8M) | ($30.6M) |
| Purchases of treasury stock | ($700.0M) | ($300.0M) | ($150.0M) | — |
| Payments of business combination contingent consideration | $0 | ($855.0K) | ($1.3M) | ($2.4M) |
| Acquisition of consolidated subsidiary | $0 | ($10.9M) | — | — |
| Proceeds from borrowings, net of borrowing costs | $0 | $0 | $105.0M | $1.1B |
| Repayment of borrowings | ($10.0M) | ($40.0M) | ($835.0M) | ($405.0M) |
| Dividends paid | ($349.7M) | ($310.9M) | ($282.3M) | ($258.3M) |
| Net cash provided by (used in) financing activities | ($1.0B) | ($606.3M) | ($1.1B) | $422.9M |
| Effect of exchange rate changes on cash | $6.2M | $25.8M | ($1.7M) | ($2.1M) |
| Net increase (decrease) in cash and cash equivalents | $259.8M | $971.1M | $10.5M | ($45.8M) |
| Cash and cash equivalents at beginning of period | $1.2B | $238.4M | $227.9M | $273.7M |
| Cash and cash equivalents at end of period | $1.5B | $1.2B | $238.4M | $227.9M |
| Income taxes paid, net of refunds | $357.2M | $214.0M | $278.4M | $216.9M |
| Interest paid | $27.1M | $28.4M | $45.7M | $47.4M |
| Fair value of assets acquired, excluding cash | $151.2M | $43.5M | $46.0M | $359.7M |
| Liabilities assumed | ($11.8M) | ($6.3M) | ($7.7M) | ($131.8M) |
| Goodwill on acquisition | $222.9M | $101.3M | $92.2M | $787.0M |
| Previously held equity investment | ($7.4M) | — | $0 | $0 |
| Deferred payments | ($1.0M) | $670.0K | ($143.0K) | $2.5M |
| Fair value of contingent consideration | ($3.2M) | $855.0K | $4.4M | ($2.4M) |
| Cash paid for acquisitions | $350.7M | $140.1M | $134.8M | $1.0B |
| Line item | Mar 31, 2026 · YTD | Dec 31, 2025 · YTD | Sep 30, 2025 · Q1 | Mar 31, 2025 · YTD |
|---|---|---|---|---|
| Net income | $1.1B | $741.1M | $348.5M | $1.0B |
| Depreciation and amortization | $156.6M | $97.6M | $47.7M | $134.8M |
| Amortization of right-of-use assets | $32.5M | $22.4M | $10.0M | $26.7M |
| Stock-based compensation costs | $76.9M | $50.1M | $21.2M | $66.9M |
| (Gain) loss attributable to equity method investments (note 5) | ($4.7M) | ($3.0M) | ($1.5M) | ($2.4M) |
| (Gain) loss on equity investments (note 5) | $16.0M | $5.9M | $6.2M | $7.8M |
| Accounts receivable | ($59.6M) | ($42.7M) | $30.0M | ($71.5M) |
| Inventories | $23.9M | $11.5M | ($14.7M) | ($48.0M) |
| Prepaid expenses, net deferred income taxes and other current assets | ($152.4M) | ($104.1M) | $2.3M | $35.6M |
| Accounts payable, accrued expenses, income taxes payable and other | $122.2M | $18.3M | $7.6M | $41.9M |
| Net cash provided by (used in) operating activities | $1.4B | $797.1M | $457.3M | $1.2B |
| Purchases of property, plant and equipment | ($105.2M) | ($71.5M) | ($43.0M) | ($59.3M) |
| Patent registration and acquisition costs | ($13.3M) | ($7.4M) | — | — |
| Purchases of intangible assets | ($1.5M) | ($1.5M) | ($2.8M) | ($7.6M) |
| Business acquisitions, net of cash acquired | ($25.4M) | ($522.0K) | ($522.0K) | ($670.0K) |
| Purchases of investments (note 5) | ($26.5M) | ($6.4M) | ($2.2M) | ($4.4M) |
| Proceeds from exits of investments (note 5) | $2.8M | $250.0K | $0 | $4.4M |
| Proceeds (payments) on maturity of foreign currency contracts | $7.6M | ($16.5M) | ($4.1M) | $1.2M |
| Net cash provided by (used in) investing activities | ($161.5M) | ($103.5M) | ($52.6M) | ($66.3M) |
| Proceeds from issuance of common stock, net | $45.2M | $37.8M | $8.2M | $44.3M |
| Taxes paid related to net share settlement of equity awards | ($21.4M) | ($21.0M) | ($719.0K) | ($17.5M) |
| Purchases of treasury stock | ($500.0M) | ($325.0M) | ($150.0M) | ($200.0M) |
| Payments of business combination contingent consideration | $0 | $0 | $0 | ($855.0K) |
| Repayment of borrowings | ($5.0M) | ($5.0M) | $0 | ($35.0M) |
| Dividends paid | ($262.6M) | ($175.3M) | ($87.8M) | ($233.3M) |
| Net cash provided by (used in) financing activities | ($743.9M) | ($488.6M) | ($230.3M) | ($442.4M) |
| Effect of exchange rate changes on cash | $5.3M | $2.7M | ($71.0K) | ($9.8M) |
| Net increase (decrease) in cash and cash equivalents | $451.1M | $207.6M | $174.4M | $694.4M |
| Cash and cash equivalents at beginning of period | $1.2B | $1.2B | $1.2B | $238.4M |
| Cash and cash equivalents at end of period | $1.7B | $1.4B | $1.4B | $932.7M |
| Income taxes paid, net of refunds | $281.1M | $209.4M | $61.9M | $197.8M |
| Interest paid | $20.0M | $13.5M | $6.9M | $21.5M |
| Fair value of assets acquired, excluding cash | $14.8M | ($798.0K) | ($798.0K) | $0 |
| Liabilities assumed | ($5.5M) | — | — | $0 |
| Goodwill on acquisition | $20.3M | $1.3M | $1.3M | $0 |
| Deferred payments | ($1.0M) | — | — | — |
| Fair value of contingent consideration | ($3.2M) | $0 | $0 | $1.5M |
| Cash paid for acquisitions | $25.4M | $522.0K | $522.0K | $1.5M |
ResMed Inc. score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.